Sandbox Reserved 1735

This Sandbox is Reserved from August 30, 2022 through May 31, 2023 for use in the course Biochemistry I taught by Kimberly Lane at the Radford University, Radford, VA, USA. This reservation includes Sandbox Reserved 1730 through Sandbox Reserved 1749.

To get started: Click the edit this page tab at the top. Click on Show preview and then Save the page after each step, then edit it again. show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page. Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc. More help: Help:Editing

HIV-1 Protease

<StructureSection load='3hvp' size='340' side='right' caption='Caption for this structure' scene=> This is a default text for your page '. Click above on edit this page' to modify. Be careful with the < and > signs. You may include any references to papers as in: the use of JSmol in Proteopedia or to the article describing Jmol to the rescue.

HIV-1 Protease in Humans

HIV-1 is more transmissible than HIV-2 and is more likely to lead to AIDS in a patient. “HIV-1 protease (PR) is a virus-encoded proteolytic enzyme that is initially systemized as part of the GagPol polyprotein” (Huang et. al, 2013). HIV-1 protease belongs to Clan AA, family A2 of the aspartic proteases. Aspartic proteases are the smallest group of proteases found in humans (Huang et. al, 2013).

The role of CD4+ T cell

The CD4+ T cell is a lymphocyte, also known as a white blood cell, that fights infection. HIV attacks the CD+ T cell by binding and replicating through the CD4 + T cell. HIV kills CD4+ T cells which results in low immunity. An HIV-infected person with very low CD4+ T cells can develop AIDS. AIDS stands for acquired immune deficiency syndrome. HIV can remain latent in the body through memory T cells. Because HIV can remain latent in the body, patients with HIV can experience periods without symptoms. Patients who do die from HIV/AIDS die from secondary infections because of their compromised immunity from low CD4+ T cells. Most infections that kill HIV/AID patients are opportunistic infections. Research suggests that HIV-1 is better at killing CD4+ T cells than HIV-2. This is one reason why HIV-1 is more likely to progress into AIDS than HIV-2 (Vijayan et. al, 2017).

Protease Inhibitors for HIV-1 Treatment

For HIV-1, protease inhibition is one method of five methods for controlling HIV-1. The HIV-1 protease protein is encoded within the pol gene. This gene holds the information for the replication of HIV. This means that the gene holds HIV-1 protease, as well as reverse transcriptase and integrase proteins (Blassel et. al, 2021). HIV-1 protease inhibitors are a method of treatment for HIV-1. However, HIV-1 protease inhibitors can lead to mutations within an individual and this is why they are classified as a treatment, but not a control. It is a constant chase to find which PR inhibitor works for a patient, and for how long it will work (Blassel et. al, 2021). HIV-1 protease inhibitors work by binding to the protease to prevent the protease from breaking down proteins. (López-Otín et. al, 2008).

Authors

Meg Burrows and Jynna Harrell